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Abstract
Plekhm1 is a large, multi-modular, adapter protein implicated in osteoclast vesicle trafficking
and bone resorption. In patients, inactivating mutations cause osteopetrosis, and gain-
of-function mutations cause osteopenia. Investigations of potential Plekhm1 interaction
partners by mass spectrometry identified TRAFD1 (FLN29), a protein previously shown to
suppress toll-like receptor signaling in monocytes/macrophages, thereby dampening in-
flammatory responses to innate immunity. We mapped the binding domains to the TRAFD1
zinc finger (aa 37-60), and to the region of Plekhm1 between its second pleckstrin homology
domain and its C1 domain (aa 784-986). RANKL slightly increased TRAFD1 levels, particu-
larly in primary osteoclasts, and the co-localization of TRAFD1 with Plekhm1 also increased
with RANKL treatment. Stable knockdown of TRAFD1 in RAW 264.7 cells inhibited resorp-
tion activity proportionally to the degree of knockdown, and inhibited acidification. The lack
of acidification occurred despite the presence of osteoclast acidification factors including
carbonic anhydrase II, a3-V-ATPase, and the ClC7 chloride channel. Secretion of TRAP
and cathepsin K were also markedly inhibited in knockdown cells. Truncated Plekhm1 in ia/
ia osteopetrotic rat cells prevented vesicle localization of Plekhm1 and TRAFD1. We con-
clude that TRAFD1, in association with Plekhm1/Rab7-positive late endosomes-early lyso-
somes, has a previously unknown role in vesicle trafficking, acidification, and resorption
in osteoclasts.
Introduction
Bone development, remodeling and repair are carried out by osteoblasts which produce bone
matrix, osteocytes which communicate the conditions inside the bones, and osteoclasts which
resorb bone [1]. Normally the activity of these cells is tightly coupled and regulated. Osteoclasts
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are multinucleated cells formed by the fusion of mononuclear progenitors of the monocyte/
macrophage family that differentiate under the influence of growth factors, macrophage-colo-
ny stimulating factor (M-CSF; CSF-1) and the TNF-related cytokine, receptor activator of
NF-κB ligand (RANKL), provided in the bone microenvironment by the osteoblasts. A major
portion of our current knowledge of osteoclast biology has come from studies of naturally-oc-
curring mutations in human patients and animals with osteopetrosis, as well as from osteope-
trosis induced by gene targeting in mice [2–5]. Osteoclasts have developed efficient and unique
machinery for dissolving mineral and degrading organic bone matrix [5,6]. When bone resorp-
tion is called for, osteoclasts migrate to the site of resorption, attach to the bone, and become
highly polarized.
Osteoclast formation from bone marrow precursors is a main point of control in bone re-
sorption, and RANKL and M-CSF are required to induce expression of genes that typify the
osteoclast [5]. RANKL binds to its receptor, RANK, on bone marrow progenitor cells and acti-
vates TNF receptor associated factors (TRAF proteins). In osteoclasts, only TRAF6 seems to
have an essential function. RANK/TRAF6 signaling induces a cascade of signaling events lead-
ing to the activation of MAP kinases, NF-κB and AP-1 [7–9]. As a result, these ligands induce
NFATc1, the transcription factor considered to be the master regulator of osteoclastogenesis
[10].
Membrane dynamics are of central importance in osteoclasts [11–13]. Differentiating osteo-
clasts develop four distinct and unique membrane domains that are essential for their function,
including a sealing zone, ruffled border, facultative secretory domain, and basolateral domain.
The first step of polarization involves rearrangement of the actin cytoskeleton and formation
of a tight junction between the bone surface and basal membrane to create a ring-like sealing
zone. The membrane adjacent to the bone surface within the sealing zone becomes highly con-
voluted, forming the ruffled border. Through the ruffled border, adjacent to the bone surface,
HCl and proteases are released. As a result, bone mineral is dissolved and the proteinaceous
matrix is digested. Carbonic anhydrase II (CAII) provides the protons; the vacuolar ATPase
(vATPase), including the essential osteoclast-specific a3-subunit, pumps the protons; and the
specialized chloride channel ClC7 provides the anions needed for electroneutrality [14]. Loss-
of-function mutations in any of those genes cause severe autosomal recessive osteopetrosis
(ARO) [4], also known as malignant osteopetrosis. Bone degradation products are then taken
up by endocytosis at the ruffled border and further degraded as they are transported by trans-
cytosis to the facultative secretory domain at the top of the polarized osteoclast for secretion
[15].
The importance of intracellular vesicle trafficking was emphasized with the discovery of two
proteins involved in that process which cause osteoclast bone disease when mutated. One is the
sorting nexin, Snx10. Snx10 regulates endosome sorting and movement through the cell. Muta-
tions in SNX10 account for roughly 4% of ARO in humans, often including an osteopetro-rick-
ets phenotype, and Snx10 is required for osteoclast differentiation and function [16–19]. The
other is Plekhm1, a large, multi-domain protein that also causes osteopetrosis in humans and
in the incisors absent (ia) rat when truncated[20], and which causes osteopenia with focal scle-
rosis when carrying a gain-of-function point mutation [21]. Plekhm1 associates with late endo-
somes/early lysosomes, binding to the small GTPase Rab7 and interacting with Rubicon to
regulate PI3 kinase-dependent vesicle movement [22]. During our investigations described
below, we used mass spectrometry to identify proteins that interact with Plekhm1 in screens of
pull-downs of cell extracts. One protein thus identified was TRAFD1 (FLN29).
TRAFD1 was first identified as an interferon- (IFN) and lipopolysaccharide- (LPS) induc-
ible factor [23]. TRAFD1 contains a TRAF-type zinc finger domain at its N-terminus and a
TRAF6-binding motif in its middle region. The TRAF6 binding motif of TRAFD1 interacts
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with the C-terminal part of TRAF6 in monocytes, and TRAFD1 also physically interacts with
other TRAF proteins (TRAF1, -2, -3) [24]. In monocytes/macrophages, TRAFD1 suppresses
the inflammatory responses to innate immunity by inhibiting Toll-like receptor 4 (TLR4) de-
pendent NF-κB and MAPK activation [23,24]. The interaction with TRAF6 led us to hypothe-
size that TRAFD1 may be important for osteoclast function.
In the present study, we confirmed and mapped in detail the interaction of TRAFD1 and
Plekhm1We also showed that TRAFD1 expression is up-regulated by RANKL, that it co-local-
izes with Plekhm1 to late endosomes, and that co-localization of TRAFD1 and Plekhm1 in-
creases after RANKL stimulation. We also show here that TRAFD1 affects osteoclast
acidification, mineral solubilization, and secretion of tartrate-resistant acid phosphatase
(TRAP) and cathepsin K. In ia/ia osteopetrotic rat osteoclasts which are unable to resorb bone,
truncated Plekhm1 prevented TRAFD1 association with vesicles.
Materials and Methods
Animals
All animals were obtained from our colonies of ia rats and C57BL/6J mice maintained at the
University of Massachusetts Medical School under specific-pathogen-free conditions, and all
procedures were in accordance with the NIH Guide for the Care and Use of Laboratory animals
and were approved by the Institutional Animal Care and Use Committee of the University of
Massachusetts Medical School. Euthanasia was performed by inhalation anesthesia followed
by decapitation.
Antibodies
The following antibodies were used in the study: rat anti-HA (clone 3F10; Roche Diagnostics,
Indianapolis, IN), mouse anti-FLAGM2 (Sigma Aldrich, St. Louis, MO), rabbit anti-lamin B1
(#ab133741; Abcam, Cambridge, MA). Goat anti-Rab7 (# sc-6563), goat anti-ClC7 (# sc-
16442), and mouse anti-CAII (# sc-166569) were purchased in Santa Cruz Biotechnology (Dal-
las, TX). Rabbit anti-Rab7 (# 2094) and rabbit anti-NFAT2 (# 8032) were purchased from Cell
Signaling Technology (Danvers, MA). Rabbit anti-cathepsin K was a gift from Dr. Eunice Lee,
Shriners Hospital for Children, Montreal, Canada; rabbit anti-TRAP was a gift from Dr. Göran
Andersson, Karolinska Institutet, Stockholm, Sweden; rabbit anti-a3-vATPase was a gift from
Dr. Beth Lee, Ohio State University, Columbus, OH. Anti-Plekhm1 antibody was raised in rab-
bits against the N-terminal 497 amino acids of human Plekhm1 protein using a standard im-
munization protocol (Capralogics Inc., Hardwick, MA), and the antiserum was affinity
purified against the immunizing protein using UltraLink Biosupport resin (Thermo Scientific,
Rockford, IL). Anti-TRAFD1 antibody was raised in chicken against whole affinity purified
human TRAFD1 protein using a standard immunization protocol (Capralogics Inc.). IgY was
precipitated from egg yolk and affinity purified with the immunizing antigen using Ultra Link
Iodoacetyl Gel resin (Thermo Scientific) according to the manufacturer’s protocol. Secondary
HRP-conjugated antibodies used for immunoblotting were: goat anti-rabbit IgG and rabbit
anti-goat IgG (Dako, Carpinteria, CA), sheep anti-mouse IgG (GE Healthcare, Piscataway, NJ),
and donkey anti-chicken IgY (Gallus Immunotech, Fergus, ON, Canada). Secondary fluores-
cent dye-conjugated antibodies used for immunofluorescence: donkey anti-chicken IgY, Alexa
488 and TRITC (#703-545-155 and 703-025-155), donkey anti-goat IgG, Alexa 488 (# 705-
486-147), and donkey anti-rabbit IgG, Alexa 568 (#711-295-152), purchased from Jackson
ImmunoResearch Laboratories Inc. (West Grove, PA). Donkey anti-rabbit IgG, Alexa 488
(#A21206) was from Life Technologies (Woburn, MA).
TRAFD1 in Osteoclast Activity
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Cell cultures
RAW264.7 and HEK 293 cells (ATCC, Manassas, VA) were maintained in α-minimum essen-
tial medium (α-MEM) or Dulbecco’s modified Eagle's medium (DMEM), respectively, supple-
mented with 10% FBS, 1% penicillin/streptomycin in a humidified incubator at 37°C in 5%
CO2. Bone marrow mononuclear cells (BMMC) and splenocytes were collected from mice
(C57BL/6J) and rats (ia strain) as described previously [20,25]. These primary mononuclear
cells were cultured in α-MEM supplemented with 75 ng/ml of recombinant human M-CSF
(Chiron Corp., Emeryville, CA). To generate osteoclasts, RAW264.7 and primary mononuclear
cells were cultured for 3–4 days in the presence of 10 ng/ml or 20 ng/ml of soluble mouse
RANKL (R&D Systems, Minneapolis, MN), respectively. Medium was changed every
other day.
shRNA gene knockdown and lentivirus gene transfer
TRAFD1-targeting shRNA in pLKO.1 vector was obtained from Sigma Aldrich (SHCLND-
NM_006700). shRNA sequences were as follows: shRNA 1: GGCTTGAGTGTGCAGCGTGT
TACCTCGAGGTAACACGCTGCACACTCAAGTTTTTG (TRCN0000339582); shRNA2:
CGGCATGCCTTACGTTCACTCAATCTCGAGATTGAGTGAACGTAAGGCATGTTTT
TG (TRCN0000339580); shRNA3: CGGCACCTACTCGATGTCTCCTAACTCGAGTTAGG
AGACATCGAGTAGGTGTTTTTG (TRCN0000339509); shRNA4: CGGCGCACACTTGGA
CTTCATGTTCTCGAGAACATGAAGTCCAAGTGTGCGTTTTTG (TRCN0000339508).
The scrambled shRNA control sequence was: CCTAAGGTTAAGTCGCCCTCGCTCGAGC
GAGGGCGACTTAACCTTAGG, generated by Sarbassov et al. [26] and obtained from
Addgene, Cambridge, MA (plasmid # 1864). shRNA constructs in the pLKO.1 vector were
packaged into lentivirus by transfection into HEK293 cells together with packaging vector
pCMV d8.2 dvpr (plasmid # 8455, Addgene) and envelope vector pCMV-VSV-G (plasmid
# 8454, Addgene). Transfections were carried out using Fugene 6 (Roche Diagnostics). Viral
supernatant was collected at 48 h post-transfection. Viral infections of RAW264.7 cells were
carried out at a multiplicity of infection of 1 with 8 μg/ml of hexadimethrine bromide. To ob-
tain stable cell lines with TRAFD1 knocked down, colonies of virally transduced RAW264.7
cells were selected by culturing in medium containing 3 μg/ml of puromycin (Sigma Aldrich).
Cells were routinely maintained in 1 μg/ml puromycin. Knock down efficiency was confirmed
using RT-qPCR with gene expression normalized to acidic ribosomal phosphoprotein P0
(Rplp0) [27].
Tandem-affinity purification and mass spectrometry
The pIRES-puro Glue vector (TAP tagged), generated by Angers et al., [28], was purchased
from Addgene (plasmid # 15100). Full-length cDNA for human Plekhm1 was amplified and
cloned into the pIRES-puro Glue vector downstream of the dual affinity tag. Construct se-
quences were verified by sequencing. The purification procedure was described previously
[28]. Briefly, cell lysate from HEK293 cells (5 × 108) stably expressing low levels of TAP-tagged
Plekhm1 was incubated overnight at 4°C with 100 μl packed volume of Streptavidin Sepharose
(GE Healthcare). Streptavidin beads were washed and protein complexes were eluted from
the streptavidin resin in calmodulin binding buffer supplemented with 50 mM biotin. The sec-
ond round of affinity purification was performed using 100 μl of Calmodulin Sepharose (GE
Healthcare). After washing, the protein complexes were eluted twice with 100 μl wash buffer
containing EGTA. The eluates were combined, run briefly into an SDS-PAGE gel, excised, and
sent to the Proteomic and Mass Spectrometry Facility at University of Massachusetts Medical
School to be digested with trypsin and analyzed by LC-MS/MS.
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Immunoprecipitation/pull down
Full-length human cDNA for Plekhm1 and various deletion mutants were PCR-amplified and
cloned into the pIRES-puro Glue vector downstream of the tandem affinity tags. The p3×FLAG-
CMV14 plasmid with human cDNA for TRAFD1 was a gift from Dr. Akihiko Yoshimura, Keio
University, Tokyo, Japan). Deletion mutants of the cDNA were PCR-amplified and cloned into
the p3×FLAG-CMV14. A 6 cm dish of HEK293T cells was transfected with p3xFLAG-CMV14-
TRAFD1 and pIRES-puro Glue–Plekhm1, either full-length or deletion mutants using Lipofecta-
mine 2000 (LifeTechnologies). 24 hours post-transfection, the cells were washed with ice-cold
PBS twice and lysed in 0.5 ml of lysis buffer (50 mMHepes-KOH pH 8.0, 100 mMKCl, 2 mM
EDTA, 0.1% Nonidet-40, 10% glycerol, 10 mMNaF, 0.5 mMNa3VO4) supplemented with fresh
2 mMDTT and protease inhibitor cocktail (Sigma Aldrich). Lysates were cleared by centrifuga-
tion and pull-downs were performed using 25 μl of Streptavidin Sepharose for 2 hours at 4°C.
After extensive washing of beads with lysis buffer, precipitated proteins were detected by immu-
noblot analysis using chemiluminescent detection. For immunoprecipitation of FLAG-tagged
TRAFD1, HEK293 cells were lysed with lysis buffer (50 mM Tris HCl pH 7.4, 150 mMNaCl,
5 mMMgCl2, 0.5% Triton-X-100 supplemented with protease inhibitor cocktail). 15 μl of
FLAG-M2 gel (Sigma Aldrich) was incubated with cell lysate for 2 hours at 4 C and pellets were
washed 5 times with wash buffer (20 mM Tris, pH7.4, 150 mMNaCl, 0.2% Triton X-100,
2.5 mMMgCl2) prior to loading onto SDS-PAGE gels for analysis.
Immunofluorescence
Cells grown on glass coverslips were fixed with 3% paraformaldehyde in PBS for 10 min, washed
with PBS, permeabilized with 1% Triton X-100, and blocked with 1% BSA with 0.05% Tween 20
in PBS. Primary and secondary antibodies were diluted in blocking solution. Primary antibodies
were used as follows: chicken anti-TRAFD1 (1:25), rabbit anti-Plekhm1 (1:1000), goat anti-Rab7
(1:100). All were incubated for 1 hour at room temperature and rinsed. Fluorescent dye-conju-
gated secondary antibodies were then incubated for 45 minutes. DAPI (Life Technologies) stain-
ing was used to label nuclei. The samples were mounted with ProLong Gold antifade reagent
(Life Technologies) and observed with a Leica SP5 (II) laser scanning confocal microscope
(Leica, Buffalo Grove, IL) equipped with 40 × (1.30 NA) and 63 × (1.4–0.6 NA) oil immersion
lenses. Leica LAS AF Lite software was used for recording and image processing.
RNA isolation and quantitative RT-PCR
RNA was extracted using RNeasy (Qiagen, Germantown, MD) and the yield determined by
measuring OD260. 1 μg of total RNA was subjected to reverse transcription with a QuantiTect
Reverse Transcription Kit (Qiagen). The resulting cDNA was used for PCR using a QuantiFast
SYBR Green PCR kit (Qiagen). Amplification reactions were performed in triplicate in 10 μl
final volume that included the following: 10–50 ng of template, 1 μM primers, 2× SYBR Green
Master Mix. Reactions were processed in a LightCycler 2 (Roche Diagnostics): 95°C for 5 min,
then 40 cycles of 95°C for 10 s and 60°C for 30 s. ΔCt for each gene was calculated and repre-
sents the difference between the Ct value for the gene of interest and that of the reference gene.
Fold-changes were calculated using the 2−ΔΔCt convention [29]. Primer sequences and the ac-
cession numbers of cDNA targets are shown in S1 Table (supplementary materials).
Resorption assay
Cells at a density 15,000/well were cultured for 10 days on Osteo Assay Surface (hydroxyapa-
tite) 24-well plates (Corning, Tewksbury, MA) under differentiation conditions. To observe
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resorption pits, plates were gently stripped of cells with 10% bleach, rinsed with distilled water,
air dried, and scanned on a flatbed scanner (Microtek 9800 XL). The percentage of resorbed
area was analyzed by NIH ImageJ software.
TRAP staining
Fixed cells were TRAP-stained using a leukocyte acid phosphatase kit (Sigma Aldrich) accord-
ing to the manufacturer’s instructions. TRAP-positive multinucleated cells containing three or
more nuclei were counted.
TRAP activity assay
RAW264.7 cells were cultured in α-MEM containing RANKL on HA plates until differentiated
(3–4 days). On the day when cells differentiated, the medium was changed. Conditioned medi-
um was collected on subsequent days 2 and 5 for measurement of TRAP activity as described
previously [30]. Absorbance was measured at 405nm. TRAP activity was calculated as the dif-
ference between wells with and without sodium molybdate.
Cathepsin K secretion assay
RAW264.7 cells were differentiated on HA plates, as above. When cells differentiated, the me-
dium was changed, and at the time points indicated, conditioned medium was collected. Cells
from each well were also collected and total cell protein extracts were prepared by lysis in RIPA
buffer. Supernatant (40 ul) and total cell lysate (50 ug) were resolved on SDS-PAGE gels, blot-
ted onto PVDF, and probed with anti-cathespin K. Blots were subsequently probed with anti-
lamin B1 antibody as a loading control.
Acidification assay
RAW264.7 cells were cultured for 5 days on Osteo Assay 24-well plates under differentiation
conditions. Acridine orange (3,6-bis[Dimethyloamine] acridine] at 10 μg/ml was loaded for 45
minutes in the culture medium. The dye was rinsed out and the cells were observed by inverted
fluorescence microscopy (Leica DMI6000) [31]. As a control, some cells were treated with the
proton pump inhibitor bafilomycin A (200 nM; Enzo Life Science, Farmingdale, NY).
Subcellular fractionation
Mononuclear cells isolated from wild-type (WT) and ia/ia rats were grown in 150 mm dishes
in the presence of RANKL (20 ng/ml) until differentiated (4 days). The cell fractionation proto-
col was adapted from [32] with modifications. Briefly, cells (1.7× 106) were washed twice with
PBS and scraped into hypo-osmotic buffer (150 mM sucrose; 10 mM Tris; 1 mM EDTA, pH
7.5 supplemented with protease inhibitor cocktail). After 5 minutes on ice, cells were homoge-
nized by 10 passes through a 23Ga needle attached to a 1 ml syringe and diluted with an equal
volume of hyper-osmotic buffer (the same as above, but with 450 mM sucrose). The cell lysate
was then centrifuged at 1000 Gav for 10 minutes at 4°C. The nuclear pellet from this centrifuga-
tion was resuspended in RIPA buffer (50 mM Tris-HCl, pH 7.4; 150 mMNaCl; 1% NP-40;
0.5% Na-deoxycholate; 0.1% SDS; 2 mM EDTA; 10 mMNaF). The post-nuclear supernatant
was collected into a new tube and centrifuged at 15,000 Gav for 15 minutes at 4°C. The pelleted
light mitochondrial fraction (LMF) was resuspended in RIPA buffer and the post-mitochondri-
al supernatant was further centrifuged at 100,000 Gav for 60 minutes at 4°C. The pelleted vesi-
cle fraction was resuspended in RIPA buffer and the remaining supernatant was saved as the
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cytosolic fraction. Protein fractions were frozen at -80°C until analyzed. Nuclear and cytosolic
cell extracts were isolated according Kloet et al. [33].
Western blotting
Protein concentrations of whole cell extracts were determined using Coomassie Plus Protein
Assay Reagent (Thermo Scientific) according to the manufacturer’s instructions. 25–150 μg of
total protein was loaded per lane for SDS-PAGE. The gels were blotted onto PVDF membranes
and probed with the following primary antibodies at the indicated dilutions: 1:10,000 Plekhm1;
1:250 TRAFD1; 1:1000 Rab7 (Cell Signaling); 1:1000 CAII, 1:2000 cathepsin K; 1:2000 TRAP;
1:3000 a3-vATPase; 1:1000 HA; 1:5000 FLAGM2; 1:500 α-tubulin; and 1:5000 lamin B1. The
appropriate horseradish peroxidase-conjugated secondary antibody was used at 1:2000 to
1:5000 dilution. Proteins of interest were visualized with ECL substrate either by film exposure
(Thermo Scientific) or Gel Doc XR+ Imaging System (Bio Rad).
Statistical analysis
All quantitative data are shown as mean + s.d. of at least three (n = 3) biological replicates for
each experiment. Two-tailed Student's t-test (Microsoft Excel or GraphPad Prism 6) was used
for statistical comparisons of two groups, while one-way ANOVA (GraphPad Prism 6) was
used to compare more than two groups. For all analyses a P-value of less than 0.05 was consid-
ered to be statistically significant.
Co-localization analysis
Co-localization analysis was done using Just Another Co-localisation Plugin (JACoP) for
Image J (NIH), in which Pearson’s correlation coefficient values were analyzed. A value of 1
represents perfect correlation, while a value close to 0 represents random correlation. To elimi-
nate the possibility of false-positives, one of the images was rotated 90° and co-localization was
measured again (S1 Fig). Values obtained were close to zero, validating the positive co-localiza-
tions in the non-rotated images [34].
Results
Identification of TRAFD1 as a Plekhm1 binding protein
Plekhm1 is a large, modular cytoplasmic protein localized to late endosomes/early lysosomes
and involved in vesicle transport and ruffled border formation in osteoclasts. Previously, we
and others identified mutations of Plekhm1 that cause osteopetrosis in rats and humans [20]
and osteopenia in a human patient [21]. In order to identify interaction partners of Plekhm1,
we performed tandem affinity purification and mass spectrometry. Human Plekhm1 fused to
the TAP tag [28] was used as bait. TRAFD1 was identified in the resulting set of potential
Plekhm1 interaction partners (not shown). To confirm and further analyze the interaction be-
tween TRAFD1 and Plekhm1, we performed a series of pull down/immunoprecipitation (IP)
experiments. TRAFD1 deletion constructs (Fig 1A, lower panel) were tested for their ability to
interact with full-length Plekhm1, and the reciprocal experiments were performed with full-
length TRAFD1 and deletion constructs of Plekhm1 (Fig 1B). Both full-length TRAFD1 and a
TRAFD1 N-terminal deletion mutant (aa Δ1–37) bound full-length Plekhm1 (Fig 1A). Further
truncations of TRAFD1 prevented binding to Plekhm1. The interacting N-terminal region of
TRAFD1 is comprised of amino acids 37–60 and is part of the zinc finger domain (28–103 aa).
Both full-length Plekhm1 and a more C-terminal region of Plekhm1 (778–986 aa) were immu-
noprecipitated with FLAG-tagged TRAFD1. Together, these results demonstrated that
TRAFD1 in Osteoclast Activity
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Plekhm1 and TRAFD1 directly interact and that the zinc finger domain of TRAFD1 is neces-
sary to bind to Plekhm1 between its second PH domain and the C1 domain.
TRAFD1 mRNA and protein levels increase during osteoclast
differentiation
Previously [24], it was shown that treatment of monocytes with lipopolysaccharide (LPS) in-
creased the level of TRAFD1 protein. To investigate the potential role of TRAFD1 in osteo-
clasts, we examined its mRNA level in osteoclast cultures. We found that RANKL caused a
slight increase in TRAFD1 mRNA in RAW264.7 cells but no change in mouse bone marrow
mononuclear cells (BMMC) (Fig 2A). Western blot analysis demonstrated that TRAFD1 pro-
tein is expressed at a low level in RAW264.7 cells and BMMC, and that RANKL caused in-
creases in TRAFD1 protein in both cell types (Fig 2B), suggesting an increase in protein
stability, at least in primary cells.
Fig 1. Binding of Plekhm1 with TRAFD1. (A) Pull-down of full-length, N-terminally TAP-tagged (streptavidin binding protein:HA:calmodulin binding protein)
Plekhm1 with TRAFD1-FLAG constructs overexpressed in HEK293 cells. Numbers of constructs in upper panel correspond to lanes in lower panel. Lysates
were pulled down with streptavidin-Sepharose followed by western blotting with anti-FLAG (middle blot). The samemembrane was probed with anti-HA
antibody to monitor pull-down efficiency of Plekhm1 (upper blot). A fraction of the lysate was also probed with anti-FLAG to control for TRAFD1 protein
expression (lower blot). Amino acids 37–60 (lane 2 and blue box), containing the zinc-finger, were required for binding to Plekhm1 (lane 2). (B) Reciprocal
experiments were done with Plekhm1 constructs diagrammed in the upper panel, with numbers corresponding to lanes in the blots in the lower panel. IP of C-
terminally FLAG-tagged full-length TRAFD1 was done with TAP-tagged Plekhm1 constructs. Lysates were immunoprecipitated with anti-FLAG-agarose,
blotted, and probed with anti-HA to detect Plekhm1 (middle blot). The samemembrane was stripped and probed with monoclonal anti-FLAG antibody to
monitor immunoprecipitation efficiency (upper blot). A fraction of the lysate was also probed with anti-HA to control for Plekhm1 protein expression (lower
blot). Amino acids 784–986 (of 1059 total), between the second PH domain and the C1 domain, were required for binding TRAFD1 (lane 4 and blue box). The
experiments were performed at least 3 times and representative gels are shown. Numbers on left show positions of molecular weight markers. ZF = zinc
finger; F = FLAG tag; T = TAP tag; R = RUN domain; * = PH domains; C = C1 domain.
doi:10.1371/journal.pone.0127537.g001
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TRAFD1 co-localizes with Plekhm1 and Rab7 in osteoclasts
In order to investigate interactions between TRAFD1 and Plekhm1 in osteoclasts, we analyzed
co-localization in BMMC by immunofluorescence. We found an increase in co-localization
upon RANKL stimulation (Fig 3A). The co-localization further increased when BMMC-de-
rived osteoclasts were actively resorbing on HA plates. Pearson’s correlation analysis showed
that co-localization of TRAFD1 and Plekhm1 increased from 0.59±0.05 in BMMC to 0.72±
0.07 and 0.80±0.04 in osteoclasts and resorbing osteoclasts, respectively (P<0.0001 for mono-
cytes vs. osteoclasts and P<0.0001 for monocytes vs. resorbing osteoclasts). Previously [20],
transfection experiments showed that fluorescently tagged Plekhm1 expressed in HEK293 cells
co-localized with GTP-bound Rab7, indicating that Plekhm1 localizes to late endosomes/early
lysosomes. To assess this in primary osteoclasts, we examined the co-localization of endoge-
nous Plekhm1 with Rab7 (Fig 3B). This confirmed that Plekhm1 strongly co-localizes with
Rab7 to late-endosomal/early-lysosomal vesicles in mononuclear cells (Pearson’s coeffi-
cient = 0.63±0.11) and the level of co-localization does not change in mature osteoclasts (Pear-
son’s coefficient = 0.66±0.05). Control analysis using 90° rotation of color channel images [34]
gave the expected, random value of 0.1±0.05, confirming the significance of the observed co-lo-
calizations. The co-localization of endogenous TRAFD1 with Plekhm1 confirms that the pro-
tein-protein interactions seen by mass spectrometry and IP assays reflect what occurs in the
cell. Further, co-localization of TRAFD1 with Rab7 (Pearson’s coefficient = 0.56±0.11 in
monocytes vs. 0.71± 0.06 in osteoclasts) places a substantial fraction of TRAFD1 in the same
cellular functional compartment as Plekhm1, i.e., late endosomes/early lysosomes of mono-
cytes and differentiated osteoclasts (S2 Fig).
TRAFD1 impacts resorbing activity of osteoclasts
In order to investigate potential functions of TRAFD1 in osteoclasts, RAW264.7 cells were
transduced with lentivirus encoding shTRAFD1, and stable clones expressing different levels of
TRAFD1 mRNA were selected (Fig 4A). When the clones were cultured with RANKL on
Osteo Assay Plates (hydroxyapatite; HA) for 10 days, defects in resorbing ability were found
that reflected the degree of TRAFD1 knockdown (Fig 4B and 4C). We used the clone with the
lowest TRAFD1 level and the lowest resorption ability, 2.6, designated hereafter as
“shTRAFD1,” in subsequent experiments.
Fig 2. Expression profile of TRAFD1 in mouse cells. (A) Transcript level of Trafd1 in RAW264.7cells (light green bars) and mouse BMMC (dark green
bars) was measured by Q-PCR in cells treated with LPS (100 ng/ml, 7 hours) or RANKL (10 ng/ml RAW264.7 cells, 20 ng/ml BMMC, 3 days). Untreated cells
were used as a control. One-way ANOVA was carried out and values are mean + standard deviation (s.d.) of 3 independent experiments. ***P<0.0001
versus control group. (B) Protein expression of TRAFD1 in RAW264.7 and mouse bone marrow mononuclear cells (BM) treated as in A. Whole cell extracts
(50 μg) were analyzed by 8% SDS-PAGE, blotted onto PVDF, and probed with anti-TRAFD1 antibody. Lamin B1 was used as a loading control. The
experiments were performed at least 3 times and representative gels are shown.
doi:10.1371/journal.pone.0127537.g002
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Due to the lack of resorption of HA by shTRAFD1 cells, we investigated their capacity to
differentiate and to express factors required for resorptive activity. As shown in Fig 5, although
they required an additional day (4 days vs. 3 days for control cells), shTRAFD1 cells did form
multinucleated, TRAP-positive cells (Fig 5A). Because we observed a delay in differentiation of
shTRAFD1cells, we examined the status of the main osteoclast transcription factor NFATc1.
In control cells, we observed increased total NFATc1 protein 24 hours after adding RANKL,
Fig 3. TRAFD1 localization in mouse BMMC. (A) Immunostaining for endogenous TRAFD1 and Plekhm1 was performed on mouse monocytes and on
mouse BMMCs treated with RANKL cultured on glass (osteoclasts), or on Osteo Assay plates (resorbing osteoclasts). Confocal microscopy images were
obtained using anti-Plekhm1 and anti-TRAFD1 (colors as indicated), and representative images are shown. DAPI staining was used to visualize nuclei.
Scale bars = 10 μm. Insets show enlarged regions outlined in white. Arrowheads indicate examples of vesicles where co-localization gives yellow signal.
Pearson’s correlation coefficient was used to estimate the co-localization of TRAFD1 with Plekhm1, where 1 represents perfect co-localization and 0 is
random co-localization. One-way ANOVA was carried out and values are mean + s.d. of n = 3 independent experiments analyzing at least 4 images/
condition. ***P<0.0001 versusmonocytes. (B) Immunostaining for endogenous Plekhm1 and Rab7 and co-localization analysis was performed as in A.
Scale bars = 10μm. Values are mean + s.d. of n = 3 independent experiments analyzing at least 4 images/condition. No significant change in co-localization
was observed ± RANKL or resorption. M = monocytes; OCs = osteoclasts; res OCs = resorbing osteoclasts.
doi:10.1371/journal.pone.0127537.g003
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and the expression increased until day 3. In shTRAFD1 cells, the NFATc1 level was slightly
lower and the translocation of NFATc1 into the nucleus was delayed compare to the control
cells, consistent with the delayed differentiation of shTRAFD1 cells (S3 Fig).
Further, those cells exhibited the actin rings characteristic of osteoclasts, as shown by fluo-
rescent labeling with phalloidin (Fig 5B). This prompted us to investigate whether the
Fig 4. TRAFD1 knockdown inhibits resorbing activity of osteoclasts. (A) Stable knockdown of TRAFD1 was achieved by transduction with lentivirus
expressing shRNA (or scrambled control) in RAW264.7 cells. Clones were selected with different degrees of knockdown in the absence of RANKL, as shown
(clones 1.7, 2.3; and 2.6). Q-PCR experiments were performed at least 3 times and representative graph shows means+ s.d. of duplicates. ***P<0.0001
versus control group. (B) Resorption assay was performed with the knockdown clones in A. Cells were cultured on 24-well Osteo Assay (HA) plates for 10
days in the presence of RANKL (10 ng/ml). Cells were removed and the plate was scanned at high resolution. Representative wells are shown on lower panel
(black = resorbed area). The percentage of resorbed area over total area of well is indicated on upper panel. Analysis of resorbed area was measured by
Image J software. One-way ANOVA was carried out and values are mean +s.d. of n = 3 independent experiments analyzing 3 wells/condition. ***P<0.0001
versus control group.
doi:10.1371/journal.pone.0127537.g004
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impaired resorption was the result of reduced levels of known acidification and resorption fac-
tors, including the ClC7 chloride channel, cathepsin K, matrix metallopeptidase 9 (MMP-9),
carbonic anhydrase II and the osteoclast-specific subunit of the vacuolar proton pump,
a3-vATPAse (Fig 6). To this end, we measured gene expression levels by Q-PCR and also eval-
uated western blots of differentiated cells. At the mRNA level, TRAP, MMP-9 and carbonic an-
hydrase II were significantly reduced (0.57±0.11, 0.7±0.1 and 0.58±0.04 respectively, P<0.05)
(Fig 6A). At the protein level, only cathepsin K showed a reduction. All the other proteins as-
sayed appeared to be present at normal levels. We also observed that differentiation of
shTRAFD1 cells with RANKL caused an increase in the level of TRAFD1 mRNA, but we did
not observe any changes in the protein level.
Since actin rings were present in shTRAFD1 cells, and protein levels of resorption factors
(with the lone exception of cathepsin K) were normal, we investigated whether acidification
was occurring properly in shTRAFD1 cells. Cells were differentiated by culturing with RANKL
for 5 days on HA plates, and then the live cells were labeled with the acidotropic probe acridine
orange (Fig 7). In this assay, osteoclast-like cells with normal acidification display orange-red
staining, indicating active production of H+ [31,35]. shTRAFD1 cells showed a loss of signal
comparable to that seen in wells treated with the proton pump inhibitor, bafilomycin A [36],
indicating a role for TRAFD1 extracellular acidification in osteoclasts. Since the proteins
Fig 5. shTRAFD1 cells differentiate in vitro. (A) Cells stably expressing TRAFD1 shRNAs were cultured on
96-well plates in the presence of RANKL (10 ng/ml), fixed, and stained for TRAP on the days indicated.
Representative micrographs are shown. Scale bar = 100 μm. (B) Rhodamine phalloidin and DAPI staining of
osteoclast-like cells cultured on glass coverslips. shTRAFD1 and control RAW264.7 cells were cultured in the
presence of RANKL (10 ng/ml) on 24-well plates with glass coverslips on the bottom. When cells
differentiated (3 days for controls, 4 days for shTRAFD1), they were fixed and stained. Representative
fluorescence micrographs are shown. Scale bar = 10 μm.
doi:10.1371/journal.pone.0127537.g005
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Fig 6. Decreased level of TRAFD1 has minor effects on expression of osteoclast resorption factors.
(A) Q-PCR analysis is shown for the indicated genes in differentiating shTRAFD1 cells (4 days in RANKL) vs.
control cells (3 days in RANKL). The expression of each gene in shTRAFD1 cells is normalized to the
expression of control cells on day 3. Student’s t-test was carried out and values are mean +s.d. of triplicate
determinations in 3 independent experiments. A representative graph is shown. *P<0.05; ***P<0.0001 versus
control. (B) Whole cell protein extracts from differentiated control cells (3 days in RANKL) and differentiated
shTRAFD1 cells (4 days in RANKL) were subjected to immunoblotting using the antibodies shown. The
experiments were performed at least 3 times and representative gels are shown.
doi:10.1371/journal.pone.0127537.g006
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required for acidification were present, the lack of acidification may reflect failure of targeting
or improper targeting of those factors.
Knockdown of TRAFD1 impairs TRAP and cathepsin K secretion
We investigated a possible role for TRAFD1 in osteoclast exocytosis by analysis of TRAP and
cathepsin K secretion. TRAP activity was measured biochemically, and cathepsin K was ana-
lyzed by western blotting (Fig 8). On day 2, TRAP activity in conditioned medium from
shTRAFD1 cells was 12-fold lower than in control cell medium (Fig 8A). Also, as shown in Fig
8B, shTRAFD1 cells secreted markedly less cathepsin K than controls. These data suggest that
TRAFD1 is important for targeting cathepsin K and TRAP to their correct location at the ruf-
fled border and are consistent with a role for TRAFD1 in osteoclast vesicle transport
and secretion.
TRAFD1 is associated with vesicles in osteoclasts and its stability is
dependent on Plekhm1
To further define the association of TRAFD1 with osteoclast vesicles, we performed sequential
ultracentrifugal fractionation of osteoclasts generated from bone marrow cells of WT rats and
splenocytes from ia/ia rats (which lack bone marrow spaces). Immunoblot analysis of the re-
sulting fractions is shown in Fig 9. In WT osteoclasts, most of the Plekhm1 was present in the
vesicle fraction (lane VF) and the cytosolic fraction (lane CF). The vesicle fraction in these sep-
arations contains endosomes and early lysosomes. Organelle-specific antibody for late endo-
somes/early lysosomes (Rab7) confirmed the enrichment of those vesicles in this fraction in
WT osteoclasts. Unlike Plekhm1, no Rab7 was detected in the cytosolic fraction. TRAFD1 ap-
peared roughly equally partitioned between the light mitochondrial fraction (LMF) lane, the
VF lane, and the CF lane. In osteoclasts generated from ia/ia rat cells, we observed that their
Fig 7. Knockdown of TRAFD1 inhibits acidification of osteoclasts. Acidification assay was performed with shTRAFD1 and control RAW264.7 cells. Cells
were cultured on 24-well Osteo Assay plates for 5 days in the presence of RANKL (10 ng/ml) and stained with acridine orange. Representative confocal
microscopy images are shown. White rectangles locate areas shown at higher magnification in insets, below. As a control for blocked acidification, some
control cells were treated with bafilomycin A (200 nM; control + baf A). Scale bar = 50 μm.
doi:10.1371/journal.pone.0127537.g007
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truncated form of Plekhm1 was primarily present mainly in the heavy nuclear pellet (lane NP)
and the CF lane, and was absent from the vesicle fraction. This mirrored the altered distribu-
tion of Rab7. TRAFD1 in ia/ia osteoclasts was detected mostly in the LMF lane; however, with
longer exposure we detected a small amount of TRAFD1 in the CF lane and the VF lane. To-
gether, these results suggest that Plekhm1 truncation disrupts both the stability and the vesicu-
lar localization of TRAFD1.
Discussion
TRAFD1, also known as FLN29, was previously linked to signaling by toll-like receptors (TLR)
and retinoic acid-inducible gene 1 (RIG-1)-like helicase (RLH), dampening the inflammatory
response in macrophages [23,24]. In those studies, TRAFD1 was found to negatively regulate
NF-κB signaling by binding to several TRAF proteins, with the TRAF6 interaction the best
characterized. In this report, we demonstrate for the first time a specific interaction between
Fig 8. TRAFD1 is required for TRAP and cathepsin K secretion. (A) Differentiated RAW 264.7 cells and
shTRAFD1 cells were grown for 5 days on Osteo Assay plates in the presence of RANKL. Conditioned media
were collected 2 and 5 days post differentiation and TRAP secretion was measured biochemically. A
representative graph is shown. One-way ANOVA was carried out and values are mean +s.d., n = 8 per time
point. ***P<0.0001 vs. controls. (B) TRAFD1 knockdown and control RAW264.7 cells were cultured on Osteo
Assay plates in the presence of RANKL. Culture supernatant (sup) was collected 24 hours post
differentiation. 40 μl of conditioned media were subjected to western blot analysis for the presence of
cathepsin K. Total cell lysates (TCL) from each well served as total protein controls. The same gel was re-
probed with lamin B1 antibody. The experiments were performed 3 times and representative gels are shown.
doi:10.1371/journal.pone.0127537.g008
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Plekhm1 and TRAFD1. Plekhm1 is important in lysosomal trafficking, secretion, ruffled bor-
der formation, and bone resorption in osteoclasts [12,20,21]. The results shown here implicate
TRAFD1 as also having a role on those processes.
The level of TRAFD1 protein in osteoclast precursors was relatively low, although it in-
creased during RANKL stimulation. We previously observed a similar pattern for Plekhm1
[20]. Confocal microscopy showed that TRAFD1 and Plekhm1 partially co-localize to late en-
dosomes, consistent with our observation of protein-protein interaction in pull-down assays.
The co-localization increased upon RANKL stimulation and was even higher in actively re-
sorbing osteoclasts. shRNA knockdown of TRAFD1 in RAW264.7 cells showed that deficiency
of TRAFD1 inhibited the resorbing capacity of osteoclast-like cells, but that actin rings formed
normally. The knockdown cells were, however, defective in acidification despite the presence
of known factors required for that process (CAII, a3-vATPase, ClC7). They were also defective
in secretion, with marked reductions in secretion of both TRAP and cathepsin K.
The amino acids of TRAFD1 which bind to Plekhm1, 37–60, are part of a TRAF-like zinc
finger domain. That domain interacts directly with amino acids 778–986 (of 1056 total) of
Plekhm1. That region of Plekhm1 lies in a conserved sequence between the second of 2 pleck-
strin homology (PH) domains and the C1/ZnF domain near the C-terminus. Those are both
required for proper interaction with the small GTPase Rab7 [22,37]. Rab7 guides late endo-
somes/early lysosomes in a GTP-dependent manner, and the GTP-bound state of Rab7 is re-
quired for its interaction with Plekhm1 [20]. We also show here that in ia/ia osteopetrotic
rat cells, which have a truncation at codon 338 of Plekhm1 (of 1059 total), TRAFD1/Rab7/
Plekhm1 interactions were disrupted. The distribution of those proteins in sequential centrifu-
gation fractions was altered. In WT osteoclasts, Plekhm1 mainly co-purified with the vesicle
fraction, and similar purification was observed for Rab7 and TRAFD1. The truncated ia/ia
Plekhm1, however, did not co-fractionate with Rab7, and the TRAFD1 level was markedly
reduced in the cell lysate and in the vesicle fraction. This suggests that the Plekhm1/Rab7/
Fig 9. TRAFD1 in osteoclast centrifugal fractionation is Plekhm1 dependent.Osteoclasts fromWT and ia/ia (Plekhm1 truncation) osteopetrotic rats
were osmotically lysed and fractionated by differential centrifugation. All fractions were subjected to western blot. 50 μg of protein from each fraction were
loaded per lane. TCL: total cell lysate; NF: nuclear fraction and cell debris; LMF: light mitochondrial and lysosomal fraction; VF: vesicle fraction; CF: cytosolic
fraction. The membrane was probed with anti-Plekhm1, anti-TRAFD1, anti-Rab7 (late endosome/early lysosomemarker), and anti-lamin B1 (nuclear
envelope marker). Truncated Plekhm1 is seen in ia/ia rats. The experiments were performed at least twice and representative gels are shown.
doi:10.1371/journal.pone.0127537.g009
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TRAFD1 interaction is important for the resorbing and secretory activities of osteoclasts and
for TRAFD1 stability.
Rab7 and Plekhm1 regulate the secretory lysosomal pathway, which delivers cathepsin K and
acidic vesicles to the ruffled border [13]. Plekhm1 is recruited to secretory lysosomes through its
interaction with Rab7. Rab7 is known to regulate the fusion between early and late endosomes
and between late endosomes and early lysosomes. Also, Rab7 regulates trafficking of late endo-
somes along microtubules in the minus direction by interaction with RILP and dynein, indicating
that Rab7 is also involved in motor protein recruitment [15,38]. Indeed, recent data on LIS1 func-
tion in osteoclasts [39] supports that model and adds further evidence linking Plekhm1 to vesicle
trafficking. That report showed that LIS1 binds to the dynein/dynactin complex and also interacts
with the RUN and PH1 domains of Plekhm1, thus mediating lysosome transport and positioning
within the cell. TRAFD1, together with Plekhm1/Rab7/LIS1, may cooperate in the delivery and/
or fusion of acidic lysosomes to the ruffled border, thereby facilitating bone resorption.
Interestingly, disruption of dynein-dynactin complexes in resorbing osteoclasts did not im-
pair acidification, but did cause a defect in cathepsin K secretion through the ruffled border
[40]. Another study showed that delivery of lysosomes to the ruffled border was blocked when
ATP6ap1 (Ac45), an accessory subunit of V-ATPases, was depleted [41]. Those authors dem-
onstrated that Ac45 directly interacts with Rab7 and may act as a bridge between the V-ATPase
and Rab7, linked to the transportation of acidic vesicles along microtubules to the ruffled bor-
der. Both Plekhm1, by interaction with Rab7, and TRAFD1, by interaction with Plekhm1, are
likely to be involved in that process. That model is consistent with our findings, in which we
show that osteoclast-like cells depleted of TRAFD1 have acidification factors present, but are
unable to acidify vesicles or the resorption lacuna to remove HA. It should be noted that acidic
vesicle/vacuole formation does occur in osteoclasts despite the presence of either inactivating
(ia/ia rat truncation; see S4 Fig) or gain-of-function (R714C in an osteopenic patient) muta-
tions in Plekhm1 [21]. The slightly higher pH of the vesicles in the R714C mutant was likely
due to an increased rate of vesicle maturation and insufficient time to fully acidify. The very
large size of the acidic vesicles in the ia/ia rat osteoclasts (S4 Fig) suggests blockage of delivery
of cargo to the ruffled border, and might explain both the pelleting of Rab7 with the relatively
heavy mitochondrial fraction and the lack of ruffled borders in ia/ia rat osteoclasts [42]. To-
gether, these observations are consistent with a model in which TRAFD1 is a key to assembly
of vesicles having proper membrane insertion and/or activity of the acidification machinery
and movement to the ruffled border.
From the results described above, we conclude: 1) TRAFD1 interacts specifically with
Plekhm1; 2) that it is required for establishment of effective acidification of the resorption lacu-
na; 3) that it is significantly associated with Rab7-positive vesicles; and 4) that it is important in
the secretory activity of resorbing osteoclasts. The importance of a clearer mechanistic under-
standing of cathepsin K secretion is underscored by the ongoing development and trials of a ca-
thepsin K inhibitor (odanacatib) to prevent bone loss and tumor metastasis to bone [43].
Cremasco and others [44] demonstrated that the mechanism of secretion of cathepsin K in os-
teoclasts is PKCδ-dependent and is independent of both ruffled border formation and
V-ATPase delivery to the ruffled border. If that dual transport model is correct, we expect that
TRAFD1 is involved in both pathways, since both secretion of cathepsin K and TRAP, and
acidification were greatly impacted by TRAFD1 deficiency.
Supporting Information
S1 Fig. Co-localization ofTRAFD1 and Plekhm1 in mouse BMMC. Co-localization analysis
was done using JACoP plugin for Image J. Pearson’s correlation coefficient values were
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analyzed using green and red channel of each image (A). As a control and to exclude false-posi-
tive results, one of the images were rotated 90°C and the co-localization was measured again
(B).
(TIF)
S2 Fig. Co-localization of TRAFD1 and Rab7 in mouse BMMC. Immunostaining for endog-
enous TRAFD1 and Rab7 was performed on mouse monocytes and on mouse monocytes treat-
ed with RANKL cultured on glass (osteoclasts). Confocal microscopy images were obtained
using anti-Rab7 (green) and anti-TRAFD1 (red), and representative images are shown. DAPI
staining was used to visualize nuclei. Scale bars = 10 μm. Insets show enlarged regions outlined
in white. Arrowheads indicate examples of vesicles where co-localization gives yellow signal.
Pearson’s correlation coefficient was used to estimate the co-localization of TRAFD1 with
Rab7 (Pearson’s coefficient = 0.56±0.11 in monocytes vs. 0.71± 0.06 in osteoclasts). Student t-
test was carried out and values are mean + s.d. of n = 3 independent experiments analyzing at
least 4 images/condition.

P<0.001 versusmonocytes. Mo = monocytes; OCs = osteoclasts.
(TIF)
S3 Fig. Protein expression of NFATc1 in shTRAFD1 cells. (A)Western blot analysis of ex-
pression levels of NFATc1 in total cell extracts from control and shTRAFD1 cells cultured in
the presence of RANKL for 1–3 days. Cells were lysed, blotted, and probed with antibody to
NFATc1. α-tubulin was used as a loading control, as indicated. (B)Western blot analysis of ex-
pression levels of NFATc1 in nuclear and cytosolic fractions of control and shTRAFD1 cells
stimulated with RANKL for 1–3 days.
(TIF)
S4 Fig. Acidification of ia/ia rat osteoclasts. Acidification assay was performed on cells from
7-day-old WT (BMMC) and ia/ia (splenocytes) rats. Cells were cultured on 24-well Osteo
Assay plates for 5 days in the presence of RANKL (20 ng/ml) and stained with acridine orange.
Representative confocal microscopy images are shown. As a control for blocked acidification,
some control cells were treated with bafilomycin A (BafA; 200 nM). Scale bar = 50 μm. Virtual-
ly all the orange staining in the ia/ia cells was in large vesicles, whereas in WT cells, there was
staining spread out, presumably under the ruffled borders, which are absent from ia/ia
rat osteoclasts.
(TIF)
S1 Table. Sequence of forward and reverse primers used in Q-PCR.
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